A detailed history of Two Sigma Securities, LLC transactions in Geron Corp stock. As of the latest transaction made, Two Sigma Securities, LLC holds 15,885 shares of GERN stock, worth $45,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,885
Holding current value
$45,272
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.17 - $4.99 $66,240 - $79,266
15,885 New
15,885 $72,000
Q2 2023

Aug 14, 2023

BUY
$1.97 - $3.69 $45,869 - $85,917
23,284 New
23,284 $74,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $80 - $141
48 Added 0.29%
16,546 $39,000
Q2 2022

Aug 15, 2022

SELL
$1.19 - $1.65 $55,012 - $76,277
-46,229 Reduced 73.7%
16,498 $26,000
Q1 2022

May 16, 2022

BUY
$0.99 - $1.6 $47,790 - $77,236
48,273 Added 333.98%
62,727 $85,000
Q4 2021

Feb 14, 2022

BUY
$1.22 - $1.72 $3,829 - $5,399
3,139 Added 27.74%
14,454 $18,000
Q3 2021

Nov 15, 2021

BUY
$1.2 - $1.5 $13,578 - $16,972
11,315 New
11,315 $16,000
Q1 2020

May 15, 2020

SELL
$0.89 - $1.49 $17,444 - $29,205
-19,601 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.27 - $1.54 $24,893 - $30,185
19,601 New
19,601 $27,000
Q2 2019

Aug 14, 2019

SELL
$1.37 - $2.02 $16,616 - $24,500
-12,129 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$1.01 - $1.83 $213 - $386
-211 Reduced 1.71%
12,129 $20,000
Q4 2018

Feb 14, 2019

BUY
$0.98 - $1.85 $12,093 - $22,829
12,340 New
12,340 $12,000
Q2 2018

Aug 14, 2018

SELL
$3.29 - $4.82 $76,318 - $111,809
-23,197 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$1.81 - $5.98 $41,986 - $138,718
23,197 New
23,197 $99,000
Q4 2017

Feb 14, 2018

SELL
$1.8 - $2.32 $26,917 - $34,693
-14,954 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$1.99 - $2.65 $29,758 - $39,628
14,954
14,954 $33,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.08B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.